Molecular Diagnostics for Cancer Drug Development

Boston, United States (June 22-23, 2010)

Co-development of molecular diagnostics and targeted cancer therapies is a game-changing strategy in oncology drug development. Identification of predictive biomarkers and their adoption into preclinical and clinical research is absolutely critical in the journey towards better cancer treatments and eventually a cure. But there are also other drivers, including:

* Reduction of attrition rates   * Streamlining of the drug development process through better candidate selection   * Meeting evolving regulatory requirements   * Ultimately, getting the right drug to the right patient.

Více: http://www.hansonwade.com/events/molecular-diagnostics-for-cancer-drug